and pemetrexed, and the targeted therapies erlotinib and gefitinib with one another. We performed systematic searches in …-line treatment, docetaxel was cost effective compared with best supportive care; erlotinib was cost effective compared with placebo …; and docetaxel and pemetrexed were dominated by erlotinib. We found indications of superiority in terms of cost …

The UK National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of erlotinib (Roche) to … submit evidence for the clinical and cost effectiveness of erlotinib as monotherapy for the maintenance treatment of patients … receiving erlotinib compared with placebo. However, no significant difference was identified in OS when patients with non …